Bolt Biotherapeutics, Inc. (BOLT) — SEC Filings
Bolt Biotherapeutics, Inc. (BOLT) — 27 SEC filings. Latest: 10-Q (Nov 12, 2025). Includes 10 8-K, 6 10-Q, 4 SC 13G/A.
View Bolt Biotherapeutics, Inc. on SEC EDGAR
Overview
Bolt Biotherapeutics, Inc. (BOLT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 12, 2025: Bolt Biotherapeutics, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $26.745 million, compared to $47.182 million for the same period in 2024, representing a 43.3% reduction. Collaboration revenue decreased by 32.5% to $5.195 million for the n
Sentiment Summary
Across 27 filings, the sentiment breakdown is: 5 bearish, 22 neutral. The dominant filing sentiment for Bolt Biotherapeutics, Inc. is neutral.
Filing Type Overview
Bolt Biotherapeutics, Inc. (BOLT) has filed 6 10-Q, 10 8-K, 3 DEF 14A, 2 10-K, 4 SC 13G/A, 1 DEFA14A, 1 SC 13D/A with the SEC between Feb 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (27)
Risk Profile
Risk Assessment: Of BOLT's 23 recent filings, 5 were flagged as high-risk, 11 as medium-risk, and 7 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $5.195M |
| Net Income | -$26.745M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $17.753M |
| Operating Margin | N/A |
| Total Assets | $65.053M |
| Total Debt | N/A |
Key Executives
- Dr. David J. Earp
- Dr. Robert L. Kirk
- Louis Rambo
- Robert Hopfner
Industry Context
The biopharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Bolt Biotherapeutics operate in a competitive landscape where innovation is key, but clinical trial success and market access are critical determinants of viability. The sector often relies on external funding and strategic partnerships to advance drug candidates.
Top Tags
corporate-governance (6) · sec-filing (4) · 10-Q (4) · delisting (3) · biotech (3) · financials (3) · proxy-statement (3) · Bolt Biotherapeutics (3) · Biotechnology (2) · Oncology (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (9 months) | $26.745M | Decreased 43.3% from $47.182M in 2024, indicating improved cost control. |
| Collaboration Revenue (9 months) | $5.195M | Decreased 32.5% from $7.690M in 2024, signaling reduced partnership income. |
| Total Operating Expense (9 months) | $34.223M | Decreased 46.4% from $63.822M in 2024, driven by R&D cuts. |
| Research and Development Expense (9 months) | $23.545M | Decreased 48.5% from $45.747M in 2024, reflecting pipeline prioritization. |
| Cash and Cash Equivalents | $17.753M | Increased from $7.205M at Dec 31, 2024, but total assets declined. |
| Accumulated Deficit | $454.1M | Significant historical losses, contributing to going concern doubt. |
| Cash and Marketable Securities | $38.8M | Management believes this will fund operations only into 2027. |
| Reverse Stock Split | 1-for-20 | Effected on June 6, 2025, impacting share count and per-share metrics. |
| Net Loss | $19.601M | Six months ended June 30, 2025, an improvement from $32.006M in 2024. |
| Collaboration Revenue | $3.026M | Six months ended June 30, 2025, down from $6.549M in 2024. |
| Research and Development Expenses | $17.010M | Six months ended June 30, 2025, a decrease from $31.962M in 2024. |
| Reverse Stock Split Ratio | 1-for-20 | Effected on June 6, 2025, to maintain listing compliance. |
| Total Assets | $75.499M | As of June 30, 2025, a decrease from $99.632M at December 31, 2024. |
| Net Cash Used in Operating Activities | $22.962M | Six months ended June 30, 2025, an improvement from $32.893M in 2024. |
| SEC File Number | 001-39988 | Identifies the company's filing with the SEC. |
Forward-Looking Statements
- {"claim":"Pivotal bioVenture Partners will continue to be a significant shareholder in Bolt Biotherapeutics.","entity":"Pivotal bioVenture Partners Fund I, L.P.","targetDate":"2025-02-12","confidence":"high"}
- {"claim":"The updated filing may lead to increased scrutiny of Bolt Biotherapeutics' stock performance.","entity":"Bolt Biotherapeutics, Inc.","targetDate":"2024-03-12","confidence":"medium"}
Frequently Asked Questions
What are the latest SEC filings for Bolt Biotherapeutics, Inc. (BOLT)?
Bolt Biotherapeutics, Inc. has 27 recent SEC filings from Feb 2024 to Nov 2025, including 10 8-K, 6 10-Q, 4 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of BOLT filings?
Across 27 filings, the sentiment breakdown is: 5 bearish, 22 neutral. The dominant sentiment is neutral.
Where can I find Bolt Biotherapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Bolt Biotherapeutics, Inc. (BOLT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Bolt Biotherapeutics, Inc.?
Key financial highlights from Bolt Biotherapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for BOLT?
The investment thesis for BOLT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Bolt Biotherapeutics, Inc.?
Key executives identified across Bolt Biotherapeutics, Inc.'s filings include Dr. David J. Earp, Dr. Robert L. Kirk, Louis Rambo, Robert Hopfner.
What are the main risk factors for Bolt Biotherapeutics, Inc. stock?
Of BOLT's 23 assessed filings, 5 were flagged high-risk, 11 medium-risk, and 7 low-risk.
What are recent predictions and forward guidance from Bolt Biotherapeutics, Inc.?
Recent forward-looking statements from Bolt Biotherapeutics, Inc. include guidance on {"claim":"Pivotal bioVenture Partners will continue to be a significant shareholder in Bolt Biotherapeutics.","entity":" and 1 other predictions.